FRANKFURT, Nov 12 (Reuters) - A late-stage trial has shown an improvement in progression-free survival in patients with advanced follicular lymphoma treated with Zevalin as a first-line therapy, Bayer (BAYG.DE: Quote, Profile, Research) said on Monday.
